Oyo州耐药结核病和药物敏感结核病患者的建模结果

O. O, Olanrewaju .s.o., Oluwasegun Agbailu ADEJUMO
{"title":"Oyo州耐药结核病和药物敏感结核病患者的建模结果","authors":"O. O, Olanrewaju .s.o., Oluwasegun Agbailu ADEJUMO","doi":"10.52589/ijphp-tq4uwzua","DOIUrl":null,"url":null,"abstract":"TB is perhaps the most important contagious disease in the world and the leading cause of mortality by an infectious disease. As a result, WHO declared that achieving the reduction in TB incidence rate for achievement of the 90-90-90 target of the END-TB strategy will be an illusion, if something severe is not done. Therefore, it is imperative to assess the visibility of achieving the END-TB goal in the country (Nigeria) by assessing the success of TB treatments so far in the country. Hence, this paper aims to model the outcome of drug-resistant-tuberculosis and drug-susceptible-tuberculosis patients in Oyo state of Nigeria using the logit function of estimating binary logistic regression model vis-à-vis identifying the success of these TB treatments. At baseline, based on WHO categorization, the study revealed the commonest cases of patients receiving DS-TB seen are ‘New’ (90.5%) followed by relapse after failure (4.2%). Contrarily, the commonest cases of patients receiving DR-TB seen are treatment after failure (44.3%), new (27.5%) and relapse after failure cases (20.6%). Four months after starting treatment, 91.5% and 3.2% were reportedly alive and dead respectively for patients receiving DS-TB treatment while 85.3% and 11.5% were reportedly alive and dead respectively for receiving DR-TB treatment. Hence, the percentage success of DS-TB recorded was higher than the recorded for DR-TB patients. Furthermore, the chi-square results for DS-TB patients indicated that mortality significantly associated with DS-TB categorised patients (i.e. Relapse) and HIV status (i.e. Negative). Also, for the DR-TB patients, the results depicted that mortality significantly associated with DR-TB categorised patients (i.e. TAF, Treatment after Loss to Follow Up and New), both HIV status and Sputum Smear status (i.e. Positive). Nevertheless, among other findings, the binary logistic regression model estimations revealed that categorised New patients and Sputum Smear status unfavourably and significantly predicted the treatment outcome (mortality) of DS-TB and DR-TB patients. As well, categorised Relapse patients unfavourably and significantly predicted the treatment outcome (mortality) of DR-TB patients. Thus, the DS-TB method of treatment is recommended in order to achieve the target goal of the END-TB strategy in Oyo state Nigeria.","PeriodicalId":341135,"journal":{"name":"International Journal of Public Health and Pharmacology","volume":"38 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Modelling Outcome of Drug Resistant Tuberculosis and Drug Susceptible Tuberculosis Patients in Oyo State\",\"authors\":\"O. O, Olanrewaju .s.o., Oluwasegun Agbailu ADEJUMO\",\"doi\":\"10.52589/ijphp-tq4uwzua\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"TB is perhaps the most important contagious disease in the world and the leading cause of mortality by an infectious disease. As a result, WHO declared that achieving the reduction in TB incidence rate for achievement of the 90-90-90 target of the END-TB strategy will be an illusion, if something severe is not done. Therefore, it is imperative to assess the visibility of achieving the END-TB goal in the country (Nigeria) by assessing the success of TB treatments so far in the country. Hence, this paper aims to model the outcome of drug-resistant-tuberculosis and drug-susceptible-tuberculosis patients in Oyo state of Nigeria using the logit function of estimating binary logistic regression model vis-à-vis identifying the success of these TB treatments. At baseline, based on WHO categorization, the study revealed the commonest cases of patients receiving DS-TB seen are ‘New’ (90.5%) followed by relapse after failure (4.2%). Contrarily, the commonest cases of patients receiving DR-TB seen are treatment after failure (44.3%), new (27.5%) and relapse after failure cases (20.6%). Four months after starting treatment, 91.5% and 3.2% were reportedly alive and dead respectively for patients receiving DS-TB treatment while 85.3% and 11.5% were reportedly alive and dead respectively for receiving DR-TB treatment. Hence, the percentage success of DS-TB recorded was higher than the recorded for DR-TB patients. Furthermore, the chi-square results for DS-TB patients indicated that mortality significantly associated with DS-TB categorised patients (i.e. Relapse) and HIV status (i.e. Negative). Also, for the DR-TB patients, the results depicted that mortality significantly associated with DR-TB categorised patients (i.e. TAF, Treatment after Loss to Follow Up and New), both HIV status and Sputum Smear status (i.e. Positive). Nevertheless, among other findings, the binary logistic regression model estimations revealed that categorised New patients and Sputum Smear status unfavourably and significantly predicted the treatment outcome (mortality) of DS-TB and DR-TB patients. As well, categorised Relapse patients unfavourably and significantly predicted the treatment outcome (mortality) of DR-TB patients. Thus, the DS-TB method of treatment is recommended in order to achieve the target goal of the END-TB strategy in Oyo state Nigeria.\",\"PeriodicalId\":341135,\"journal\":{\"name\":\"International Journal of Public Health and Pharmacology\",\"volume\":\"38 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-02-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Public Health and Pharmacology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.52589/ijphp-tq4uwzua\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Public Health and Pharmacology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.52589/ijphp-tq4uwzua","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

结核病可能是世界上最重要的传染病,也是传染病导致死亡的主要原因。因此,世卫组织宣布,如果不采取严厉措施,实现减少结核病发病率以实现终止结核病战略的90-90-90目标将是一种幻想。因此,必须通过评估该国迄今为止结核病治疗的成功情况来评估该国(尼日利亚)实现终末结核病目标的可见度。因此,本文旨在利用估计二元逻辑回归模型-à-vis的logit函数对尼日利亚Oyo州耐药结核病和药敏结核病患者的结果进行建模,以确定这些结核病治疗的成功程度。在基线时,根据世卫组织的分类,该研究显示,接受DS-TB治疗的患者中最常见的病例是“新发”(90.5%),其次是失败后复发(4.2%)。相反,最常见的耐药结核病患者是失败后治疗(44.3%)、新发病例(27.5%)和失败后复发病例(20.6%)。开始治疗4个月后,接受DS-TB治疗的患者报告生存率和死亡率分别为91.5%和3.2%,而接受DR-TB治疗的患者报告生存率和死亡率分别为85.3%和11.5%。因此,DS-TB记录的成功率高于DR-TB患者记录的成功率。此外,DS-TB患者的卡方结果表明,死亡率与DS-TB分类患者(即复发)和HIV状态(即阴性)显著相关。此外,对于耐药结核病患者,结果显示死亡率与耐药结核病分类患者(即TAF,失去随访后的治疗和新的),艾滋病毒状态和痰涂片状态(即阳性)显着相关。然而,在其他发现中,二元logistic回归模型估计显示,分类的新患者和痰涂片状态不利且显著地预测了DS-TB和DR-TB患者的治疗结果(死亡率)。此外,对复发患者进行不利分类并显著预测耐药结核病患者的治疗结果(死亡率)。因此,建议采用DS-TB治疗方法,以便在尼日利亚奥约州实现终止结核病战略的具体目标。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Modelling Outcome of Drug Resistant Tuberculosis and Drug Susceptible Tuberculosis Patients in Oyo State
TB is perhaps the most important contagious disease in the world and the leading cause of mortality by an infectious disease. As a result, WHO declared that achieving the reduction in TB incidence rate for achievement of the 90-90-90 target of the END-TB strategy will be an illusion, if something severe is not done. Therefore, it is imperative to assess the visibility of achieving the END-TB goal in the country (Nigeria) by assessing the success of TB treatments so far in the country. Hence, this paper aims to model the outcome of drug-resistant-tuberculosis and drug-susceptible-tuberculosis patients in Oyo state of Nigeria using the logit function of estimating binary logistic regression model vis-à-vis identifying the success of these TB treatments. At baseline, based on WHO categorization, the study revealed the commonest cases of patients receiving DS-TB seen are ‘New’ (90.5%) followed by relapse after failure (4.2%). Contrarily, the commonest cases of patients receiving DR-TB seen are treatment after failure (44.3%), new (27.5%) and relapse after failure cases (20.6%). Four months after starting treatment, 91.5% and 3.2% were reportedly alive and dead respectively for patients receiving DS-TB treatment while 85.3% and 11.5% were reportedly alive and dead respectively for receiving DR-TB treatment. Hence, the percentage success of DS-TB recorded was higher than the recorded for DR-TB patients. Furthermore, the chi-square results for DS-TB patients indicated that mortality significantly associated with DS-TB categorised patients (i.e. Relapse) and HIV status (i.e. Negative). Also, for the DR-TB patients, the results depicted that mortality significantly associated with DR-TB categorised patients (i.e. TAF, Treatment after Loss to Follow Up and New), both HIV status and Sputum Smear status (i.e. Positive). Nevertheless, among other findings, the binary logistic regression model estimations revealed that categorised New patients and Sputum Smear status unfavourably and significantly predicted the treatment outcome (mortality) of DS-TB and DR-TB patients. As well, categorised Relapse patients unfavourably and significantly predicted the treatment outcome (mortality) of DR-TB patients. Thus, the DS-TB method of treatment is recommended in order to achieve the target goal of the END-TB strategy in Oyo state Nigeria.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信